Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Deakin

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Arthritis Research & Therapy|August 17, 2018
Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort studyE H Pieter van Dijkhuizen, Maria De Iorio, Lucy R Wedderburn, et al.
Pediatric Rheumatology Online Journal|September 26, 2021
JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathologyMeredyth G Ll Wilkinson, Claire T Deakin, Charalampia Papadopoulou, et al.
Blood|March 17, 2007
Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptorsChristine M Smyth, Samantha L Ginn, Claire T Deakin, et al.
Frontiers in Immunology|January 9, 2019
Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring ToolsJudith Wienke, Claire T Deakin, Lucy R Wedderburn, et al.
Arthritis Research & Therapy|April 16, 2020
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patientsRaquel Campanilho-Marques, Claire T Deakin, Stefania Simou, et al.
Rheumatology Advances in Practice|September 20, 2021
A survey to understand the feelings towards and impact of COVID-19 on the households of juvenile dermato myositis patients from a parent or carer perspectiveMeredyth Grace Llewellyn Wilkinson, Wing Wu, Kathryn O'Brien, et al.
Internal Medicine Journal|November 27, 2023
Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savingsClaire T Deakin, Geoffrey O Littlejohn, Hedley Griffiths, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 18, 2018
Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural ModelingClaire T Deakin, Raquel Campanilho-Marques, Stefania Simou, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 11, 2009
Can peer educators influence healthy eating in people with diabetes? Results of a randomized controlled trialJ E Cade, S F L Kirk, P Nelson, et al.
International Journal of Rheumatic Diseases|February 5, 2025
The Relationship Between Patient-Reported Quality of Life and Physician-Derived Clinical Outcomes in Rheumatoid Arthritis in the Australian OPAL DatasetGeoffrey Littlejohn, Nithila Anbumurali, Catherine O'Sullivan, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Arthritis Research & Therapy|August 17, 2018
Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort studyE H Pieter van Dijkhuizen, Maria De Iorio, Lucy R Wedderburn, et al.
Pediatric Rheumatology Online Journal|September 26, 2021
JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathologyMeredyth G Ll Wilkinson, Claire T Deakin, Charalampia Papadopoulou, et al.
Blood|March 17, 2007
Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptorsChristine M Smyth, Samantha L Ginn, Claire T Deakin, et al.
Frontiers in Immunology|January 9, 2019
Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring ToolsJudith Wienke, Claire T Deakin, Lucy R Wedderburn, et al.
Arthritis Research & Therapy|April 16, 2020
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patientsRaquel Campanilho-Marques, Claire T Deakin, Stefania Simou, et al.
Rheumatology Advances in Practice|September 20, 2021
A survey to understand the feelings towards and impact of COVID-19 on the households of juvenile dermato myositis patients from a parent or carer perspectiveMeredyth Grace Llewellyn Wilkinson, Wing Wu, Kathryn O'Brien, et al.
Internal Medicine Journal|November 27, 2023
Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savingsClaire T Deakin, Geoffrey O Littlejohn, Hedley Griffiths, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 18, 2018
Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural ModelingClaire T Deakin, Raquel Campanilho-Marques, Stefania Simou, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 11, 2009
Can peer educators influence healthy eating in people with diabetes? Results of a randomized controlled trialJ E Cade, S F L Kirk, P Nelson, et al.
International Journal of Rheumatic Diseases|February 5, 2025
The Relationship Between Patient-Reported Quality of Life and Physician-Derived Clinical Outcomes in Rheumatoid Arthritis in the Australian OPAL DatasetGeoffrey Littlejohn, Nithila Anbumurali, Catherine O'Sullivan, et al.
Pageof 5